Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Cytosorbents Corp (CTSO)
|
Add to portfolio |
|
|
|
| Price: |
$9.25
| | Metrics |
| OS: |
43.7
|
M
| |
-93
|
% ROE
|
| Market cap: |
$404
|
M
| |
-86
|
% ROIC
|
|
Net cash:
|
$17.1
|
M
| |
$0.39
|
per share
|
|
EV:
|
$387
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($30.6)
|
M
| |
|
|
|
EBIT
|
($31.5)
|
M
| |
|
|
| EPS |
($0.75)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 34.7 | 43.2 | 41.0 | 24.9 | 22.5 | 15.2 | 9.5 | 4.8 |
| Revenue growth | -19.6% | 5.3% | 64.4% | 10.9% | 48.5% | 59.0% | 98.8% | 16.2% |
| Cost of goods sold | 14.0 | 11.0 | 11.1 | 7.4 | 7.5 | 5.5 | 4.0 | 2.2 |
| Gross profit | 20.7 | 32.1 | 30.0 | 17.6 | 15.0 | 9.6 | 5.6 | 2.6 |
| Gross margin | 59.8% | 74.4% | 73.0% | 70.5% | 66.7% | 63.6% | 58.5% | 53.8% |
| Selling, general and administrative | 37.1 | 38.5 | 31.5 | 24.5 | 22.9 | 16.3 | 13.0 | 8.0 |
| Research and development | 15.1 | 16.4 | 8.8 | 12.1 | 7.7 | 3.2 | 4.1 | 3.9 |
| General and administrative | 2.8 | 2.7 | 3.0 | 2.5 | 2.0 | 1.3 | 1.2 | 1.1 |
| EBITA | -31.5 | -22.7 | -10.4 | -19.0 | -15.6 | -9.8 | -11.5 | -9.3 |
| EBITA margin | -90.9% | -52.7% | -25.3% | -76.0% | -69.3% | -65.0% | -120.3% | -194.2% |
| Amortization of intangibles | | | | | | | 0.0 | |
| EBIT | -31.5 | -22.7 | -10.4 | -19.0 | -15.6 | -9.8 | -11.5 | -9.3 |
| EBIT margin | -90.9% | -52.7% | -25.3% | -76.0% | -69.3% | -65.0% | -120.6% | -194.2% |
| Pre-tax income | -33.9 | -25.3 | -9.0 | -20.4 | -17.8 | -9.1 | -12.1 | -9.8 |
| Income taxes | -1.1 | -0.7 | -1.1 | -1.1 | -0.6 | -0.7 | -0.3 | -0.3 |
| Tax rate | 3.2% | 2.9% | 12.6% | 5.4% | 3.5% | 7.4% | 2.6% | 3.3% |
| Net income | -32.8 | -24.6 | -7.8 | -19.3 | -17.2 | -8.8 | -11.8 | -9.5 |
| Net margin | -94.6% | -56.9% | -19.1% | -77.2% | -76.5% | -58.1% | -123.5% | -197.8% |
| |
| Diluted EPS | ($0.75) | ($0.57) | ($0.20) | ($0.60) | ($0.56) | ($0.32) | ($0.46) | ($0.38) |
| Shares outstanding (diluted) | 43.6 | 43.4 | 38.8 | 32.3 | 30.7 | 27.6 | 25.4 | 24.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|